Mercer Global Advisors Inc. ADV Has $1.65 Million Stock Holdings in Smith & Nephew plc (NYSE:SNN)

Mercer Global Advisors Inc. ADV cut its position in shares of Smith & Nephew plc (NYSE:SNN) by 7.7% during the 2nd quarter, Holdings Channel reports. The firm owned 66,524 shares of the medical equipment provider’s stock after selling 5,577 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Smith & Nephew were worth $1,648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of SNN. Optiver Holding B.V. increased its stake in shares of Smith & Nephew by 100.4% during the 4th quarter. Optiver Holding B.V. now owns 599,981 shares of the medical equipment provider’s stock worth $16,476,000 after purchasing an additional 300,591 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Smith & Nephew by 80.1% during the 4th quarter. Hsbc Holdings PLC now owns 592,734 shares of the medical equipment provider’s stock worth $16,152,000 after buying an additional 263,641 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Smith & Nephew by 58.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock worth $12,995,000 after buying an additional 193,046 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Smith & Nephew by 20.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after buying an additional 173,448 shares during the period. Finally, Tocqueville Asset Management L.P. boosted its holdings in shares of Smith & Nephew by 294.9% during the 1st quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock worth $5,692,000 after buying an additional 167,599 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew Trading Down 0.4 %

NYSE SNN opened at $30.55 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. Smith & Nephew plc has a 12-month low of $21.52 and a 12-month high of $31.72. The firm has a 50-day moving average price of $30.20 and a two-hundred day moving average price of $27.13.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 4th will be issued a $0.288 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a yield of 2.4%. This is an increase from Smith & Nephew’s previous semi-annual dividend of $0.24.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Smith & Nephew in a report on Wednesday, July 24th. They set a “buy” rating for the company. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Monday, August 5th. Finally, UBS Group raised shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday, June 5th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Smith & Nephew has an average rating of “Moderate Buy”.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.